WholesaleInvestor

08 May 2010

Atlantic Healthcare - Production commencing for the use of Alicaforsen in named patients

Atlantic Healthcare’s first drug – alicaforsen – a breakthrough treatment for Inflammatory Bowel Diseases, is about to go into production ahead of launch.

Atlantic Healthcare acquired the global rights to alicaforsen, targeting gastro-intestinal inflammation from Isis Pharmaceuticals Inc.

Poised for international expansion, Isis is participating in Atlantic’s Share Offer, to launch alicaforsen under the named patient supply regulations and take the company into profitability. With clear and strong product differentiation and peak sales potential of $320m, alicaforsen is being supplied in response to market demand and patient need.

Breaking news from Europe:

Professor Derek Jewell, Professor of Gastroenterology at The University of Oxford and one of Europe’s leading specialists in Inflammatory Bowel Disease has agreed to Chair the European Medical Advisory Board for Atlantic Healthcare.

With a very strong management team of “asset hunters”, a sound strategy for acquisitions and rapid commercialisation, expect further similar exciting products to be acquired which can bring early returns to investors.

For more information

www.atlantichc.com

steve.hobbs@atlantichc.com

To view the Atlantic Healthcare page please CLICK HERE.